JPMorgan analyst Lisa Gill downgraded GoodRx (GDRX) to Neutral from Overweight.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx: Weakened Long‑Term Outlook and Structural Headwinds Support Sell Rating
- Closing Bell Movers: Nvidia pares post-earnings gains
- GoodRx sees FY26 revenue $750M-$780M, consensus $815.89M
- GoodRx reports Q4 adjusted EPS 9c, consensus 9c
- GoodRx Holdings options imply 10.2% move in share price post-earnings